MJoTAtalks

Dr Susanna's guide to

www.MJoTA.org
click here

www.MJoTAtalks.org click here

www.drsusanna.org click here



Dr Susanna loves the countries and the peoples of Africa
 
Bookmark and Share
Diabetes news from the American Diabetes Association

Latest Top (20) News
Diabetes News
Diabetes news from the National Institutes of Health Diabetes Educators.

Latest Top (10) News
Clinical trials testing therapies for diabetes

Latest Top (10) News


A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon®
Condition:   Diabetic Retinopathy
Interventions:   Drug: Vitis vinifera extract;   Drug: Calcium Dobesilate;   Drug: Placebo
Sponsors:   Hanyang University;   Hanlim Pharm. Co., Ltd.
Completed

Fri, 24 May 2019 12:00:00 EDT


Clinical Assessment of a Novel Advanced Bolus Calculator for Type 1 Diabetes 5
Condition:   Type 1 Diabetes Mellitus
Interventions:   Device: ABC4D;   Device: Standard Bolus Calculator
Sponsors:   Imperial College London;   DexCom, Inc.
Recruiting

Fri, 24 May 2019 12:00:00 EDT


Cognitive Function and Body Mass Index in Children and Adolescents
Conditions:   Obesity, Childhood;   Obesity, Adolescent;   Cognitive Orientation
Intervention:  
Sponsors:   Imperial College London Diabetes Centre;   Georgetown University
Recruiting

Fri, 24 May 2019 12:00:00 EDT


Effect of mCPP on Cognitive Control, Appetite, and Neural Responses
Conditions:   Eating Behavior;   Obesity
Interventions:   Drug: mCPP;   Drug: Placebo oral tablet
Sponsors:   University of Birmingham;   University Hospital Birmingham
Recruiting

Fri, 24 May 2019 12:00:00 EDT


Molecular Mechanisms and Carotid Atherosclerosis
Conditions:   Diabetes Mellitus, Type 2;   Atherosclerosis of Artery;   Atherosclerotic Plaque
Intervention:   Drug: MetFORMIN 1000 Mg Oral Tablet
Sponsor:   University of Campania "Luigi Vanvitelli"
Completed

Fri, 24 May 2019 12:00:00 EDT


A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus
Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: GX-G6;   Drug: Control
Sponsor:   Genexine, Inc.
Not yet recruiting

Thu, 23 May 2019 12:00:00 EDT


Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation
Condition:   Pre Diabetes
Intervention:   Drug: Exenatide SR
Sponsor:   Mayo Clinic
Recruiting

Thu, 23 May 2019 12:00:00 EDT


EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds
Conditions:   Surgical Wound;   Diabetes;   Amputation Wound;   Incision Wound;   Peripheral Arterial Disease;   Breast Cancer;   Diabetic Foot
Intervention:   Device: Transcu O2®
Sponsors:   Baylor College of Medicine;   Electrochemical Oxygen Concepts, Inc.
Recruiting

Thu, 23 May 2019 12:00:00 EDT


Effect of Adiposity and Associated Local Microbial Factors on Healing and Progression of Diabetic Foot Ulcers
Condition:   Diabetic Foot Ulcer
Intervention:   Other: Normal standard care
Sponsors:   Muhimbili University of Health and Allied Sciences;   GlaxoSmithKline
Not yet recruiting

Thu, 23 May 2019 12:00:00 EDT


Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
Conditions:   Pre-Eclampsia;   Hypertension in Pregnancy;   Obesity
Interventions:   Drug: Aspirin 81 mg;   Drug: Aspirin 162 mg
Sponsor:   The University of Texas Health Science Center, Houston
Recruiting

Thu, 23 May 2019 12:00:00 EDT
Don't get diabetes! Take care of yourself if you have it! Diabetes resources, click here.
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.

Latest Top (10) News


FDA Statement on the agency’s list of known nitrosamine-free valsartan and ARB class medicines, as part of agency’s ongoing efforts to resolve ongoing safety issue
FDA announces list of nitrosamine-free ARB medications confirmed by the agency to help patients and healthcare providers




FDA Warns Against the Use of Unauthorized Devices for Diabetes Management
FDA Warns Against the Use of Unauthorized Devices for Diabetes Management




FDA alerts hospitals, laboratories and health care professionals about recall of Beckman Coulter blood test analyzers due to risk of inaccurate platelet analyzing results
FDA alerts hospitals, laboratories and health care professionals about recall of Beckman Coulter blood test analyzers due to risk of inaccurate platelet analyzing results




FDA approves first PI3K inhibitor for breast cancer
FDA approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant.




FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots
The FDA approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older.




FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality
FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality




FDA authorizes marketing of first diagnostic test for detecting Zika virus antibodies
FDA authorizes marketing of first diagnostic test for detecting Zika virus antibodies




FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea
FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea




FDA permits marketing of first diagnostic test to aid in detecting prosthetic joint infections
FDA permits marketing of first diagnostic test to aid in detecting prosthetic joint infections




FDA takes action to protect women’s health, orders manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse to stop selling all devices
FDA informs companies that the agency is not approving their PMA applications and that they will have to remove their products from the market